Amarin Corporation/$AMRN
1D1W1MYTD1Y5YMAX
Capital at risk
About Amarin Corporation
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
- Ticker
- $AMRN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 80
- Headquarters
- Dublin, Ireland
- Website
- www.amarincorp.com
AMRN Metrics
BasicAdvanced
$293M
-
-$1.30
0.76
-
Price and volume
Market cap
$293M
Beta
0.76
52-week high
$20.90
52-week low
$12.96
Average daily volume
70K
Financial strength
Current ratio
3.671
Quick ratio
2.491
Long term debt to equity
0.012
Total debt to equity
0.016
Interest coverage (TTM)
-3,419.86%
Profitability
EBITDA (TTM)
-21.095
Gross margin (TTM)
41.96%
Net profit margin (TTM)
-14.56%
Operating margin (TTM)
-12.85%
Effective tax rate (TTM)
-6.12%
Revenue per employee (TTM)
$2,330,000
Management effectiveness
Return on assets (TTM)
-2.31%
Return on equity (TTM)
-5.97%
Valuation
Price to revenue (TTM)
1.555
Price to book
0.66
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
18.601
Free cash flow yield (TTM)
5.38%
Free cash flow per share (TTM)
0.746
Growth
Revenue change (TTM)
-15.10%
Earnings per share change (TTM)
-74.13%
3-year revenue growth (CAGR)
-18.68%
10-year revenue growth (CAGR)
5.72%
3-year earnings per share growth (CAGR)
-11.73%
10-year earnings per share growth (CAGR)
-18.93%
Upcoming events
No upcoming events
AMRN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.